This study will examine the efficacy, safety and effect on hemoglobin levels, of once weekly subcutaneous injections of epoetin beta (30,000 IU) in anemic participants with non-Hodgkin's lymphoma, chronic lymphocytic leukemia or multiple myeloma. The anticipated study duration is 4 months, and the target sample size is 30 individuals.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
4
Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 g/dL versus baseline.
Unnamed facility
Caracas, Venezuela
Unnamed facility
Caracas, Venezuela
Hemoglobin levels at 16 weeks
Time frame: 16 Weeks
Serum Iron, Ferritin and Transferrin Levels
Time frame: 16 Weeks
Time to Global Response
Time frame: Up to 4 months
Percentage of Participants with a Positive Response
Time frame: Weeks 4 and 8
Quality of Life in Relation to Grade of Anemia
Time frame: Up to 4 months
Quality of Life According to the Functional Assessment of Cancer Therapy - Anemia (FACT-An) Instrument
Time frame: Up to 4 months
Tolerability - Incidence of Adverse Events
Time frame: Up to 16 Weeks of treatment period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.